The assessment of antichymotrypsin in cancer monitoring.
A comparative study of serum antichymotrypsin, acid glycoprotein and antitrypsin levels has been made in various cancers. Antichymotrypsin (ACT) shows a non-specific elevation in metastatic cancer, and the response reflects tumour progression in a similar fashion to the other two acute phase reactant proteins. The main advantage of ACT as a marker appears to be its Normal distribution in health, and lack of phenotypic variation.
D000469:Alkaline Phosphatase / Q000097:blood; D002272:Carcinoembryonic Antigen / Q000032:analysis; D002918:Chymotrypsin / Q000037:antagonists & inhibitors*; D005260:Female; D005770:Gastrointestinal Neoplasms / Q000097:blood; D006801:Humans; D008297:Male; D009362:Neoplasm Metastasis; D009369:Neoplasms / Q000097:blood*; D009961:Orosomucoid / Q000032:analysis; D011247:Pregnancy; D000515:alpha 1-Antitrypsin / Q000032:analysis; D005723:gamma-Glutamyltransferase / Q000097:blood
D002272:Carcinoembryonic Antigen; D009961:Orosomucoid; D000515:alpha 1-Antitrypsin; D005723:gamma-Glutamyltransferase; D000469:Alkaline Phosphatase; D002918:Chymotrypsin